瑞士Octapharma www.octapharma.com
总部位于瑞士 Lachen 的 Octapharma Group 是全球最大的血浆制品制造商之一，过去25年多来一直致力于病患护理和医疗创新。Octapharma 的核心业务是从人类血浆和人类细胞系中开发、生产和销售高品质的人类蛋白质疗法，其中包括免疫球蛋白静脉注射 (IGIV)。在美国，Octapharma 的 IGIV 产品 octagam(R)（5%免疫球蛋白[人体]静脉注射液）被用于治疗各种免疫系统疾病，而该公司的 Albumin（人体）则能够恢复和维持循环血量。Octapharma 拥有3000多名员工，并在包括美国在内的全球80个国家拥有生物制药经验。Octapharma USA 坐落于新泽西州霍伯肯。Octapharma 经营着两家经美国 FDA 许可的一流生产基地，最大程度地提高了生产灵活性，并将产品短缺降至最低。
瑞士Octapharma
Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality human proteins.
The company has grown to 3,000 employees in 28 countries since its founding in 1983. Octapharma owns five modern, state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico. Sales turnover in 2008 reached Euro 886 million.
Octapharma continues to grow and invest heavily in the future. Profits, are mainly channelled into R&D and further improvements and expansion of Production.
In the highly demanding market of life-saving plasma products, company success is only possible through reliable product quality and a proven safety record.

Octapharma Mission
Since the foundation of Octapharma in 1983, the company has established a clear and consistent mission: for the safe and optimal use of plasma.
This mission statement has stood the test of time and has driven our activities in the last 26 years.
Over the past six years, in addition to our plasma-based activities, Octapharma has dedicated increasing resources to recombinant product research and development based on the use of human cell lines.
Our recombinant R&D department in Sweden has completed pre-clinical toxicology testing in animals and clinical trials in humans will start in 2009.
This unique approach sets us apart from other companies whose recombinant products are based on animal (murine) cells.

For the safe and optimal use of human proteins
Octapharma respects donated human plasma as a scarce and valuable resource. By using leading edge, validated viral inactivation and purification technologies Octapharma aims to achieve the highest production yields and produce products with the highest possible safety margins.